High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children
- 1 June 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 45 (2) , 133-136
- https://doi.org/10.1097/qai.0b013e31805c9d52
Abstract
Efavirenz-containing regimens using concentration-controlled dosing have been shown to provide potent antiretroviral activity in children. In many settings, concentration-controlled dosing is not available. In this study, efavirenz plasma concentrations were evaluated in South African HIV-infected children receiving efavirenz-based antiretroviral treatment. Three consecutive blood samples were drawn between 12 and 24 hours after dosing in 15 HIV-infected children receiving the recommended daily doses of efavirenz. Validated liquid chromatography tandem mass spectrometry methods were used to determine plasma levels of efavirenz. The trough concentration (Cmin) of efavirenz was estimated by extrapolation of the log-linear regression line of the 3 concentration versus time points to 24 hours. The estimated Cmin was <1 mg/L in 6 (40%) of the children. Three of the 5 children with detectable viral loads had low efavirenz concentrations. Marked bimodality in efavirenz concentrations was observed. Our findings, together with those of previous studies, indicate that many children dosed according to the current guidelines do not achieve adequate efavirenz exposure. Because low efavirenz concentrations are associated with the rapid emergence of efavirenz-resistant mutations and treatment failure, the current recommended efavirenz doses should be re-evaluated, especially in developing countries, where therapeutic drug monitoring is seldom available.Keywords
This publication has 12 references indexed in Scilit:
- Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissuesPharmacogenetics and Genomics, 2006
- Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenzPharmacogenetics and Genomics, 2006
- Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral EfficacyAIDS Research and Human Retroviruses, 2006
- Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutationsAIDS, 2004
- Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochemical and Biophysical Research Communications, 2004
- Efavirenz Plasma Concentrations in HIV-Infected PatientsTherapeutic Drug Monitoring, 2004
- Intrapatient Variability of Efavirenz Concentrations as a Predictor of Virologic Response to Antiretroviral TherapyAntimicrobial Agents and Chemotherapy, 2004
- Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionClinical Pharmacology & Therapeutics, 2003
- Published by Elsevier ,2002
- Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1999